4//SEC Filing
Relypsa Inc 4
Accession 0001140361-16-078616
CIK 0001416792operating
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 12:25 PM ET
Size
21.8 KB
Accession
0001140361-16-078616
Insider Transaction Report
Form 4
Relypsa IncRLYP
BALL KRISTINE M
Chief Financial Officer & SVP
Transactions
- Disposition from Tender
Common Stock
2016-09-01$32.00/sh−11,922$381,504→ 20,355 total - Disposition to Issuer
Stock Option (Right to Buy)
2016-09-01−122,872→ 0 totalExercise: $3.96Exp: 2022-12-04→ Common Stock (122,872 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-09-01−38,500→ 0 totalExercise: $28.38Exp: 2025-08-09→ Common Stock (38,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-09-01−43,603→ 0 totalExercise: $7.40Exp: 2023-07-23→ Common Stock (43,603 underlying) - Award
Common Stock
2016-09-01+4,167→ 32,277 total - Disposition to Issuer
Common Stock
2016-09-01$32.00/sh−20,355$651,360→ 0 total - Award
Stock Option (Right to Buy)
2016-09-01+16,667→ 25,000 totalExercise: $18.87From: 2016-09-01Exp: 2025-11-05→ Common Stock (16,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-09-01−25,000→ 0 totalExercise: $18.87Exp: 2025-11-05→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-09-01−35,000→ 0 totalExercise: $27.21Exp: 2024-08-13→ Common Stock (35,000 underlying)
Footnotes (4)
- [F1]On November 6, 2015, the Reporting Person was granted 6,250 Restricted Stock Units to vest upon achievement of certain performance-based milestones (the "Performance RSUs"). On June 3, 2016, 1/3rd of the Performance RSUs vested upon achievement of the first performance milestone. On September 1, 2016, the vesting of the remaining Performance RSUs accelerated in full with any performance condition being deemed achieved at 100% pursuant to the terms of the Agreement and Plan of Merger, dated as of July 20, 2016 (the "Merger Agreement"), by and among the Issuer, Galencia AG, a public limited company existing under the laws of Switzerland ("Parent"), and Vifor Pharma USA Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent.
- [F2]Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $32.00 per share, without interest, subject to any applicable withholding taxes.
- [F3]Pursuant to the terms of the Merger Agreement, on September 1, 2016, each award of restricted stock units and stock options was cancelled in exchange for the right to receive $32.00 per share in cash less any applicable withholding taxes and in the case of stock options, less the applicable exercise price.
- [F4]On November 6, 2015, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock to vest in three equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On June 3, 2016, 1/3rd of the Performance Option vested upon achievement of the first performance milestone. On September 1, 2016, the vesting of the remaining unvested shares subject to the Performance Option accelerated in full with any performance condition being deemed achieved at 100% pursuant to the terms of the Merger Agreement.
Documents
Issuer
Relypsa Inc
CIK 0001416792
Entity typeoperating
Related Parties
1- filerCIK 0001416792
Filing Metadata
- Form type
- 4
- Filed
- Sep 1, 8:00 PM ET
- Accepted
- Sep 2, 12:25 PM ET
- Size
- 21.8 KB